Abstract
Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers have slightly different mechanisms of action. As such, it has been hypothesized that these 2 classes of medications differ in their ability to prevent myocardial infarction. In the present case-control study, we found no difference between angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in the primary prevention of nonfatal myocardial infarction among patients with hypertension.
Publication types
-
Clinical Trial
-
Controlled Clinical Trial
-
Multicenter Study
-
Research Support, Non-U.S. Gov't
-
Research Support, U.S. Gov't, P.H.S.
MeSH terms
-
Adult
-
Aged
-
Angiotensin Receptor Antagonists*
-
Angiotensin-Converting Enzyme Inhibitors / adverse effects
-
Angiotensin-Converting Enzyme Inhibitors / therapeutic use*
-
Antihypertensive Agents / adverse effects
-
Antihypertensive Agents / therapeutic use*
-
Case-Control Studies
-
Female
-
Humans
-
Hypertension / drug therapy*
-
Hypertension / epidemiology
-
Male
-
Middle Aged
-
Multivariate Analysis
-
Myocardial Infarction / epidemiology
-
Myocardial Infarction / prevention & control*
-
Prospective Studies
-
Risk Factors
-
Treatment Outcome
Substances
-
Angiotensin Receptor Antagonists
-
Angiotensin-Converting Enzyme Inhibitors
-
Antihypertensive Agents